Apollo Therapeutics raises $33.5m in Series C second close led by Patient Square Capital.
The funding will support clinical development and drug discovery programmes derived from academic research.
≈ £26.4M at $1 = £0.7891 on 3 Jan 2024
A Cambridge-headquartered biopharmaceutical company focused on translating fundamental medical research into innovative medicines through a hub-and-spoke portfolio model.
Apollo Therapeutics has completed the second close of its Series C financing round with an additional $33.5m, bringing its total raised capital to $260m. The round was led by Patient Square Capital, with participation from M&G plc, two major US public pension plans, and existing backer Rock Springs Capital.
The company will direct the new capital toward advancing its pipeline programmes through clinical development, supporting drug discovery activities derived from partner institution research, and licensing or acquiring additional clinical-stage programmes.
From the founder
"We are delighted to have completed the second close of our Series C financing in December and thank existing investors for their additional support, as well as welcoming new shareholders to the Company,"
Richard Mason
CEO at Apollo Therapeutics
Use of funds
- 01Fund research and development
- 02Continue product development
- 03Fund acquisitions
Investors
About the company
Apollo Therapeutics
Apollo Therapeutics develops innovative medicines based on academic medical research breakthroughs.